Tag: mental health tips

  • The future of psychiatry depends on whether DSM-6 has the courage to say something unpopular

    The future of psychiatry depends on whether DSM-6 has the courage to say something unpopular

    My latest article in Psychiatric Times  https://www.psychiatrictimes.com/view/psychiatry-does-not-need-a-softer-dsm-it-needs-a-smarter-one

    Not all distress is disease

    That does not minimize suffering

    It protects the seriousness of psychiatric illness

    Some people have schizophrenia, bipolar disorder, OCD, severe depression, catatonia, and other conditions that can devastate lives without accurate diagnosis and treatment

    Others are suffering from trauma, stress, grief, substance use, medical illness, social collapse, personality structure, or environmental chaos

    They still deserve care

    But care does not always require a lifelong diagnostic label

    That is the tension DSM-6 must confront

    If the next DSM becomes broader, softer, and more flexible without becoming more scientifically valid, psychiatry will not gain credibility. It will lose it.

    My latest article in Psychiatric Times argues that psychiatry does not need a softer DSM.

    It needs a smarter one.

  • Mental Illness Is Real. Not Everything Painful Is

    Mental Illness Is Real. Not Everything Painful Is

    On the two opposite ways psychiatry harms patients, and the discipline to know the difference.

    There are two dangerous ways to talk about mental illness, and most public conversation manages to do both at once.

    The first is to deny that it exists.

    The second is to see it everywhere.

    Both are wrong. Both are harmful. Both leave patients worse off.

    On one side are the people who claim psychiatric disease isn’t real, that we’re medicating normal emotion, that diagnosis is social construction, that psychiatry exists to enrich pharmaceutical companies and serve as gatekeepers for a coercive system.

    This is the most extreme antipsychiatry position. And anyone who has actually worked with the seriously mentally ill knows how detached from reality it is.

    Anyone who has sat with a patient in the middle of a manic episode, watched schizophrenia consume a young person’s future, or cared for a loved one whose personality and functioning were permanently altered by illness knows that serious mental illness is not a metaphor. It is not a branding problem. It is not a failure of social acceptance.

    It is real.

    It destroys lives.

    It fractures families.

    It changes the trajectory of everyone around it.

    To deny that is not compassionate. It is cruel.

    But there is a subtler version of denial, one that doesn’t reject psychiatric illness outright, but explains nearly everything through the lens of trauma.

    I don’t mean trauma in the strict PTSD sense. Not the defined clinical syndrome with intrusive memories, avoidance, negative alterations in mood and cognition, and hyperarousal. I mean the broader cultural reflex to frame almost every form of suffering, dysregulation, or dysfunction as “trauma.”

    Trauma matters. Adverse experiences shape brain development, attachment, emotional regulation, interpersonal functioning, substance use, and psychiatric vulnerability. Trauma-informed care has improved medicine, especially by reminding clinicians not to mistake survival strategies for character flaws.

    But trauma does not explain everything.

    It does not explain every case of bipolar disorder. It does not explain every case of schizophrenia. It does not explain every recurrent psychotic episode, every manic state, every severe melancholic depression, or every disabling case of OCD.

    Sometimes the illness is the illness.

    Sometimes the problem is not that society failed to understand a person’s pain. Sometimes the problem is that a devastating psychiatric disease has emerged, and without treatment, it will keep dismantling that person’s life.

    But the opposite error is just as common, and at least as harmful.

    Some clinicians see mental illness in everything.

    They accept every DSM category as if it were a blood test result. They are not critical enough of psychiatry’s limitations. They recognize suffering, and because they want to help, they reach for diagnosis. They reach for medication. They reach for neuromodulation. They reach for a treatment plan that looks medical, billable, and actionable.

    But not every form of suffering is a psychiatric disease.

    Some suffering is grief.

    Some suffering is loneliness.

    Some suffering is moral injury.

    Some suffering is poverty.

    Some suffering is addiction, family chaos, social collapse, lack of purpose, bad relationships, unemployment, burnout, or the consequences of repeated poor decisions.

    Some suffering is just the pain of being human in a world that doesn’t give people much room to fall apart.

    That doesn’t make it fake. It doesn’t mean the person doesn’t deserve help.

    It means the help they need may not live inside a pill bottle.

    This is one of the hardest conversations in psychiatry.

    A patient is suffering. Their family is desperate. Everyone wants the problem named. Everyone wants the plan, the timeline, the medication, the diagnosis, the insurance code, the discharge plan, the promise that things will get better quickly.

    But sometimes the honest answer is:

    “I believe you are suffering. I believe you need help. But I am not convinced that what you have is best understood as a medication-responsive psychiatric disease.”

    That is not abandonment. That is clinical honesty.

    And it is much harder than simply prescribing something.

    The pressure to diagnose is everywhere.

    Families want answers. Hospitals need billable codes. Insurance companies require DSM or ICD diagnoses. Patients often arrive already convinced that if their suffering is severe enough, it must be a disorder. Clinicians are trained inside systems where diagnosis drives reimbursement, treatment authorization, length of stay, documentation, and discharge planning.

    The incentives quietly push us toward overdiagnosis.

    Not always because clinicians are careless. Often because that is simply how the system works.

    A person presents in crisis. They are admitted to an inpatient psychiatric unit. The system expects a psychiatric diagnosis. But not everything that gets someone admitted to inpatient psychiatry is caused by a primary psychiatric disease.

    Sometimes it is. Absolutely. Sometimes it is mania, psychosis, melancholic depression, catatonia, severe OCD, or a lethal depressive episode.

    Those cases need aggressive, evidence-based psychiatric treatment. Medication can be lifesaving. ECT can be lifesaving. Lithium, clozapine, antipsychotics, long-acting injectables, lifesaving. We should never minimize that. Untreated serious mental illness can destroy the patient’s life and the family’s along with it.

    But other times the picture is far more complicated. There may be interpersonal chaos, substance use, housing instability, personality structure, trauma history, family conflict, legal problems, financial collapse, social isolation, or a profound absence of coping skills. The person is suffering, but the suffering does not map cleanly onto a discrete psychiatric disease.

    These patients often respond poorly to medication, because medication was never the main answer.

    Then, when the medication doesn’t work, everyone assumes the psychiatrist chose the wrong one.

    Try another SSRI. Add an antipsychotic. Add a mood stabilizer. Try ketamine. Try TMS. Try something stronger.

    But sometimes the problem isn’t treatment resistance.

    Sometimes the problem is diagnostic overreach.

    This is where psychiatry must be honest with itself.

    We can harm people in two opposite directions.

    We can harm them by failing to diagnose and treat real mental illness.

    We can harm them by diagnosing and treating something as mental illness when it isn’t.

    The first error leaves people untreated and at the mercy of their disease.

    The second exposes people to unnecessary treatment, side effects, identity shifts, stigma, financial cost, and the disappointment that follows when a promised medical solution fails to deliver.

    And when people are harmed by treatments they didn’t need, they often become psychiatry’s loudest critics.

    Not because they were always antipsychiatry.

    Because psychiatry overpromised. Because someone gave them a diagnosis that didn’t fit. Because someone medicalized their suffering without understanding their life.

    Psychiatry does not need to choose between naïve biological reductionism and total diagnostic nihilism. We need a more disciplined middle.

    When there is a clear psychiatric illness, recognizable course, symptom pattern, family history, severity, treatment-responsive biology, we should treat it seriously and decisively. No apologies. No hesitation. No pretending that schizophrenia is just “difference,” or mania is “spiritual awakening,” or severe depression is “sadness,” or OCD is “perfectionism.”

    But when the presentation is questionable, when the course doesn’t fit, when the diagnosis is being stretched to justify intervention, when the suffering is real but not clearly disease-based, we should slow down.

    We should listen longer. Widen the frame. Ask whether medication is likely to help. Consider psychotherapy, structure, sleep, substance use treatment, social repair, family boundaries, vocational support, lifestyle change, and time.

    We should be willing to say:

    “This is real suffering. But I am not going to pretend that a psychiatric label explains all of it.”

    That isn’t minimizing. That’s precision.

    The future of psychiatry depends on our ability to hold both truths at the same time.

    Mental illness is real.

    And not everything painful is mental illness.

    Some people desperately need psychiatric treatment and will be devastated without it. Others need compassion, structure, therapy, accountability, community, and support, but not a diagnosis that follows them for life, or medications that may do more harm than good.

    The goal is not to diagnose less. The goal is to diagnose better.

    The goal is not to medicate everyone. The goal is to treat the right condition, in the right person, at the right time, for the right reason.

    That is the psychiatry I believe in.

    Not psychiatry as social control.

    Not psychiatry as a pill for every problem.

    Psychiatry as a serious medical discipline, one that recognizes disease reality, respects human suffering, and has the humility to know the difference.

  • Reject dogma—embrace nuance in Psychiatry

    🔹 Psychoanalysis should not be treated as sacred doctrine. Freud was a clever and influential thinker, but not a prophet.


    🔹 Biological psychiatry is equally vulnerable to dogma. Not every symptom signals a disease, and not every distress warrants medication.


    🔹 That said, evidence-based pharmacology has its place—especially when medications show clear, replicable benefits in defined clinical conditions.

    The future of psychiatry lies in balanced thinking, not blind allegiance—to Freud, to biology, or to any single model of mind.

  • Avoid Tianeptine: FDA Alerts Consumers to Risks

    Avoid Tianeptine: FDA Alerts Consumers to Risks

    The U.S. Food and Drug Administration (FDA) has issued a critical health warning about the growing availability of tianeptine, a dangerous, unapproved substance being sold as a dietary supplement under names like Zaza, Tianna Red, Pegasus, and others.

    Commonly referred to as “gas station heroin”, tianeptine mimics opioid-like effects and is being sold in convenience stores, gas stations, smoke shops, and online—posing serious health risks to the public.

    ⚠️ Why This Matters:

    Tianeptine is not approved for any medical use in the U.S. Despite this, it is widely marketed for supposed benefits like mood enhancement, anxiety relief, or cognitive boost. These claims are not supported by clinical evidence, and the risks are significant.

    🩺 Serious Health Risks Associated With Tianeptine:

    ⚠️ Death, particularly when combined with alcohol or other substances

    ⚠️ Respiratory depression (slow or stopped breathing)

    ⚠️ Seizures

    ⚠️ Loss of consciousness

    ⚠️ Confusion and agitation

    ⚠️ Opioid-like withdrawal symptoms

    🛑 What You Can Do:

    Report adverse reactions to the FDA via MedWatch: https://www.fda.gov/medwatch

    Avoid any products labeled as containing tianeptine.

    Do not trust unregulated supplements marketed for mental clarity or energy.

    📌 Quick Summary:

    • Tianeptine = dangerous, unapproved opioid-like drug
    • Sold as a supplement under names like Zaza or Tianna Red
    • Linked to seizures, coma, and death
    • Avoid these products and warn others
    • Report side effects to the FDA MedWatch Program
  • The Importance of Distinguishing Suicidal Behaviors

    The Importance of Distinguishing Suicidal Behaviors

    This is the subject of a recent discussion I had with a colleague regarding the differences between a suicide attempt and a suicide gesture. Though these terms are sometimes used interchangeably in casual conversation or even in clinical documentation, they carry fundamentally different meanings—both in terms of patient risk and in how we, as clinicians, should respond.

    Our conversation emerged from a case involving a patient with borderline personality disorder who presented to the emergency department after ingesting a small quantity of over-the-counter medication. The intent was unclear. Was this a serious attempt to end her life? Or was it a gesture—an act of desperation without the intention to die, but rather to communicate emotional distress?

    The question is not academic. Our interpretation of the event determines our risk formulation, our documentation, our treatment planning, and even how we communicate with the patient and their support system. Yet, it is precisely in these gray areas that clinicians often struggle, and where outdated or stigmatizing language can do real harm.

    Defining the Terms: Clinical and Functional Differences

    suicide attempt refers to an act of self-harm with at least some intent to die. The degree of lethality may vary, but what distinguishes an attempt is that the individual believed the act could result in death and engaged in it with that goal in mind—even if ambivalence was present. The National Institute of Mental Health (NIMH) and the Columbia-Suicide Severity Rating Scale (C-SSRS) define this with some specificity: any potentially self-injurious behavior with non-zerointent to die, regardless of outcome.

    In contrast, a suicidal gesture is a behavior that mimics suicidal behavior or appears life-threatening but is typically not intended to be fatal. The function is often communicative or affect-regulating rather than aimed at death. Classic examples include superficial wrist-cutting, ingesting a sub-lethal dose of medication, or tying a noose but not tightening it. These acts often occur in interpersonal contexts and can be seen as efforts to signal pain, elicit help, or assert control in the face of perceived abandonment.

    Why the Distinction Matters

    It might be tempting to dismiss suicidal gestures as “attention-seeking” or “manipulative,” but this framing is both clinically dangerous and ethically fraught. Individuals who engage in gestures often experience intense psychological suffering, and repeated gestures are a well-established risk factor for future suicide attempts and completed suicide.

    From a risk assessment standpoint, gestures should be taken seriously, especially when they become part of a pattern. While the intent to die may not be present in a given gesture, intent can shift quickly, particularly in individuals with mood disorders, personality pathology, or under the influence of substances.

    From a treatment perspective, understanding the function of the behavior—whether it is to relieve affective tension, to communicate distress, or to punish oneself—is crucial to tailoring interventions. For instance, dialectical behavior therapy (DBT) explicitly targets self-harm and suicidal gestures as part of its hierarchy of treatment priorities, recognizing the urgency and potential danger of these behaviors even when lethality is low.

    Conclusion: Clarify, Don’t Categorize

    Ultimately, the conversation with my colleague reminded me that the real clinical challenge is not to label a behavior as a suicide attempt or a gesture, but to understand its meaning in the life of the patient. Both require empathy, structure, and a willingness to engage with complexity. Whether a patient wants to die or wants their suffering to be seen and acknowledged, both deserve serious clinical attention.

    By sharpening our definitions and approaching these behaviors with nuance, we can better serve patients in crisis and avoid the pitfalls of assumptions—especially in emotionally charged clinical environments like emergency rooms, inpatient units, or high-acuity outpatient settings.

  • 🧠 New Research Alert! 🧠

    🧠 New Research Alert! 🧠

    A study in JAMA Psychiatry explores how functional MRI (fMRI) biomarkers can help distinguish major depressive disorder (MDD) 😔 from healthy individuals. Researchers found that regional homogeneity (ReHo) patterns in the brain are a more reliable marker for MDD than traditional structural MRI 🏗️.

    🔬 Why does this matter?
    👉 Better Diagnostics: fMRI could lead to more objective ways to diagnose depression, reducing reliance on self-reporting.
    👉 Early Detection: One day, brain scans 🏥 might help identify people at risk before symptoms fully develop.
    👉 Personalized Treatment: Understanding individual brain patterns could help guide targeted interventions like therapy or medication.

    Could brain scans be the future of depression diagnosis? 🤔 Drop your thoughts below! ⬇️

    📖 Read more: jamanetwork.com

  • 🚨 New Study Links Antidepressant Use to Significant Weight Gain Over 6 Years! 

    🚨 New Study Links Antidepressant Use to Significant Weight Gain Over 6 Years! 

    A recent study published in Frontiers in Psychiatry reveals that individuals using antidepressants experienced notable weight gain over a six-year period.​

    Key Findings:

    • Increased Weight Gain:
      • Participants who used antidepressants showed an average weight increase of approximately 2% of their baseline body weight compared to non-users.​
    • Higher Obesity Risk:
      • Those without obesity at the study’s start had double the risk of becoming obese if they used antidepressants throughout the six years.​

    Implications:

    With the widespread use of antidepressants and the global obesity epidemic, integrating weight management and metabolic monitoring into depression treatment plans is crucial.​

    link: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1464898/full

  • Major Federal Healthcare Cuts: What Physicians Need to Know and How We Can Respond

    Major Federal Healthcare Cuts: What Physicians Need to Know and How We Can Respond

    A devastating blow to public health: More than $12 billion in federal grants—funding that supported infectious disease tracking, mental health services, addiction treatment, and other critical programs—has been canceled as part of recent federal budget cuts.

    These cuts threaten early detection of outbreaksaccess to psychiatric care, and lifesaving addiction treatment programs—all areas where we, as physicians, see the impact daily.

    Key Areas Affected:

    🚨 Infectious Disease Surveillance – Reduced ability to track emerging threats like COVID-19, flu, and antibiotic-resistant infections.
    🧠 Mental Health Services – Fewer resources for crisis response teams, community mental health centers, and psychiatric services.
    💉 Addiction Treatment – Less funding for MAT (medication-assisted treatment) and harm reduction programs at a time when overdose rates remain high.
    🏥 Public Health Preparedness – Cuts to pandemic readiness and emergency response training for healthcare workers.

    What Can We Do?

    🔹 Advocate – Contact legislators, professional organizations (APA, AMA, ACP), and demand restoration of funding.
    🔹 Educate – Inform patients and communities about how these cuts impact their care.
    🔹 Mobilize – Work with hospital leadership and local organizations to find alternative funding sources.
    🔹 Collaborate – Strengthen interprofessional partnerships to sustain services despite budget constraints.

    We’ve seen what happens when public health is underfunded—it costs more lives and more money in the long run. We can’t afford to be silent.

  • Managing Mild to Severe Depression: A Guide to Treatment Approaches

    Managing Mild to Severe Depression: A Guide to Treatment Approaches

    It is crucial to recognize that none of the available medications or neuromodulation procedures, including electroconvulsive therapy (ECT) and psychedelics, are disease-modifying. This means that while these treatments can alleviate symptoms, they do not address the underlying causes of depression. Think of them like acetaminophen for a fever—it may temporarily reduce the fever, but without treating the underlying infection, the fever will return.

    Neuromodulation refers to techniques that alter brain activity through electrical or magnetic stimulation. Examples include ECT, transcranial magnetic stimulation (TMS), and vagus nerve stimulation (VNS), all of which have been explored as treatments for severe depression.

    Optimizing Depression Treatment for Different Severity Levels

    Given this understanding, how can we best utilize these treatments to support patients during difficult times? The key is to acknowledge that medications and neuromodulation primarily serve as symptom management tools, most effectively used in the short term for severe cases.

    Mild to Moderate Depression: Prioritizing Non-Medication Approaches

    For individuals experiencing mild to moderate depression, medication should not be the first line of treFor individuals experiencing mild to moderate depression, medication should not be the first line of treatment. Many people can directly link their depressive symptoms to stressful life events. In such cases, the best initial approach includes:

    • Cognitive Behavioral Therapy (CBT) – Evidence-based therapy that helps reframe negative thinking patterns. Research has shown that CBT is as effective as antidepressants for mild to moderate depression, with relapse rates significantly reduced in those who complete therapy.
    • Lifestyle Modifications – Regular exercise and a healthy diet have strong evidence supporting their role in reducing depressive symptoms. A study published in JAMA Psychiatry found that individuals engaging in at least 150 minutes of moderate exercise per week had a 25% lower risk of developing depression.

    For some, these interventions alone may be sufficient to overcome depression and maintain long-term well-being. If additional support is needed, natural supplements with reasonable evidence, such as St. John’s Wort and S-Adenosylmethionine (SAMe), may be considered for mild to moderate depression. However, these supplements are not without risks—St. John’s Wort can interact with many medications, including antidepressants and birth control pills, potentially reducing their effectiveness. SAMe may cause gastrointestinal discomfort or manic symptoms in individuals with bipolar disorder.

    Severe Depression: When Medication and Neuromodulation Play a Role

    For individuals with severe depression, particularly those at risk for self-harm or suicide, the risks and benefits of medication should be carefully weighed. Antidepressants and neuromodulation therapies have demonstrated the most significant impact in these cases. When selecting a medication, I prioritize those with a lower risk of concerning side effects, particularly sexual dysfunction. My initial choices often include:

    • Bupropion – A dopamine-norepinephrine reuptake inhibitor with a favorable side effect profile.
    • Vortioxetine – Known for its cognitive benefits and relatively low sexual side effects.
    • Mirtazapine – Can be beneficial for those with sleep disturbances or appetite loss.
    • Vilazodone – A serotonin modulator with a lower incidence of sexual dysfunction compared to SSRIs.

    It is essential for patients starting antidepressants to be closely monitored, especially in the early weeks of treatment, to assess for side effects and response. Regular follow-ups with a healthcare provider can help adjust dosages or explore alternative treatments if needed.

    Treatment Duration and Discontinuation Considerations

    For those starting medication, I generally recommend continuing treatment for 6 to 12 months, followed by an assessment to determine whether tapering off is feasible. This process involves shared decision-making, considering:

    • Symptom severity and stability
    • Level of daily functioning
    • Patient’s goals and preferences

    The goal is to ensure that the patient has developed effective coping strategies, engaged in therapy, and adopted a healthy lifestyle before considering medication discontinuation. If stopping medication is not advisable, we work to identify the lowest effective dose for long-term maintenance.

    Final Thoughts

    Depression treatment should be personalized and dynamic, evolving with the patient’s needs. By recognizing that medications and neuromodulation are tools for symptom management rather than cures, we can ensure they are used effectively—providing relief during crises while prioritizing long-term strategies for resilience and recovery.